About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 932010, 9 pages
http://dx.doi.org/10.1155/2013/932010
Review Article

Lenalidomide and Chronic Lymphocytic Leukemia

1Department of Hematology, Hospital Universitario Central de Asturias, C/Celestino Villamil s/n, 33006 Oviedo, Spain
2Department of Functional Biology, IUOPA, Universidad de Oviedo, C/Julián Claveria s/n, 33006 Oviedo, Spain
3Department of Hematology, Hospital de Cabueñes, C/ Cabueñes s/n, 33394 Gijón, Spain

Received 28 May 2013; Accepted 7 August 2013

Academic Editor: Alessandro Isidori

Copyright © 2013 Ana Pilar González-Rodríguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance. This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies.